이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Cue Biopharma 관리
관리 기준 확인 2/4
Cue Biopharma's CEO는 Dan Passeri, Aug2016 에 임명되었습니다 의 임기는 7.83 년입니다. 총 연간 보상은 $ 3.02M, 20.1% 로 구성됩니다. 20.1% 급여 및 79.9% 보너스(회사 주식 및 옵션 포함). 는 $ 181.68K 가치에 해당하는 회사 주식의 0.28% 직접 소유합니다. 181.68K. 경영진과 이사회의 평균 재임 기간은 각각 6.1 년과 6 년입니다.
주요 정보
Dan Passeri
최고 경영자
US$3.0m
총 보상
| CEO 급여 비율 | 20.1% |
| CEO 임기 | 7.8yrs |
| CEO 소유권 | 0.3% |
| 경영진 평균 재임 기간 | 6.1yrs |
| 이사회 평균 재임 기간 | 5.9yrs |
최근 관리 업데이트
Recent updates
Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money
Apr 16
Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?
Dec 30Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?
Aug 11Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug
Oct 04Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt
Sep 23News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat
Aug 26Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates
Aug 10Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%
May 18Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
May 12Cue Biopharma: A First Assessment
May 11Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Mar 19Cue Biopharma: Too Long To Arrive At Topline Trial Data
Feb 23We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth
Nov 04Cue Biopharma doses first patient in trial for CUE-101 in head and neck cancer
Jun 10Companies Like Cue Biopharma (NASDAQ:CUE) Are In A Position To Invest In Growth
Jun 07Cue Biopharma's CUE-101 shows encouraging action in HPV+ head and neck cancer patients
May 10How Many Cue Biopharma, Inc. (NASDAQ:CUE) Shares Did Insiders Buy, In The Last Year?
Mar 21We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate
Feb 22Is Cue Biopharma, Inc. (NASDAQ:CUE) Popular Amongst Insiders?
Jan 27
Cue Biopharma: CUE-101's Phase 1 Promising Progress, 1 New IND Expected, Funding Until Q2 2022
Jan 07Reflecting on Cue Biopharma's (NASDAQ:CUE) Share Price Returns Over The Last Year
Dec 25Independent Director Aaron Fletcher Just Bought 3.9% More Shares In Cue Biopharma, Inc. (NASDAQ:CUE)
Nov 29We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate
Nov 24CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$50m |
| Dec 31 2023 | US$3m | US$605k | -US$51m |
| Sep 30 2023 | n/a | n/a | -US$52m |
| Jun 30 2023 | n/a | n/a | -US$52m |
| Mar 31 2023 | n/a | n/a | -US$52m |
| Dec 31 2022 | US$1m | US$748k | -US$53m |
| Sep 30 2022 | n/a | n/a | -US$47m |
| Jun 30 2022 | n/a | n/a | -US$49m |
| Mar 31 2022 | n/a | n/a | -US$46m |
| Dec 31 2021 | US$2m | US$531k | -US$44m |
| Sep 30 2021 | n/a | n/a | -US$47m |
| Jun 30 2021 | n/a | n/a | -US$44m |
| Mar 31 2021 | n/a | n/a | -US$44m |
| Dec 31 2020 | US$6m | US$501k | -US$45m |
| Sep 30 2020 | n/a | n/a | -US$43m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$38m |
| Dec 31 2019 | US$1m | US$395k | -US$37m |
| Sep 30 2019 | n/a | n/a | -US$39m |
| Jun 30 2019 | n/a | n/a | -US$45m |
| Mar 31 2019 | n/a | n/a | -US$43m |
| Dec 31 2018 | US$834k | US$345k | -US$39m |
| Sep 30 2018 | n/a | n/a | -US$38m |
| Jun 30 2018 | n/a | n/a | -US$30m |
| Mar 31 2018 | n/a | n/a | -US$27m |
| Dec 31 2017 | US$410k | US$325k | -US$23m |
보상 대 시장: Dan 의 총 보상 ($USD 3.02M )은 US 시장( $USD 683.56K ).
보상과 수익: 회사가 수익성이 없는 동안 Dan 의 보상이 증가했습니다.
CEO
Dan Passeri (63 yo)
7.8yrs
테뉴어
US$3,015,480
보상
Mr. Daniel R. Passeri, also known as Dan, MSc. J.D. has been the Chief Executive Officer and Director of Cue Biopharma, Inc. since August 2016 and also served as its President since August 2016 until Octob...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Director | 7.8yrs | US$3.02m | 0.28% $ 166.9k | |
| President & Chief Scientific Officer | 6.1yrs | US$1.21m | 0.28% $ 168.2k | |
| Chief Financial Officer | 6.1yrs | US$1.16m | 0.029% $ 17.7k | |
| Co-Founder | no data | US$316.63k | 데이터 없음 | |
| Co-Founder & Senior Advisor | no data | US$316.63k | 데이터 없음 | |
| Co-Founder and Chairman of Scientific & Clinical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Senior VP | 6.5yrs | US$625.51k | 데이터 없음 | |
| Chief Medical Officer | 3.3yrs | 데이터 없음 | 0.019% $ 11.4k |
6.1yrs
평균 재임 기간
54.5yo
평균 연령
경험이 풍부한 관리: CUE 의 관리팀은 노련하고 경험 (평균 재직 기간 6.1 년)입니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Director | 7.8yrs | US$3.02m | 0.28% $ 166.9k | |
| Co-Founder and Chairman of Scientific & Clinical Advisory Board | 9.4yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 6yrs | US$76.31k | 0% $ 0 | |
| Independent Chairman of the Board | 5.9yrs | US$106.27k | 0.058% $ 34.7k | |
| Independent Director | 8.3yrs | US$144.18k | 0.00073% $ 440.3 | |
| Member of Scientific & Clinical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 1.3yrs | 데이터 없음 | 데이터 없음 | |
| Clinical Advisor | 1.4yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 1.2yrs | US$135.31k | 0.017% $ 10.1k | |
| Member of Scientific Advisory Board | 3.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific & Clinical Advisory Board | 7.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 3.3yrs | 데이터 없음 | 데이터 없음 |
5.9yrs
평균 재임 기간
64yo
평균 연령
경험이 풍부한 이사회: CUE 의 이사회는 경험(평균 재직 기간 6 년)으로 간주됩니다.